• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

探索基于模型的经济评估中的结构不确定性。

Exploring structural uncertainty in model-based economic evaluations.

作者信息

Afzali Hossein Haji Ali, Karnon Jonathan

机构信息

School of Population Health, The University of Adelaide, Level 7, 178 North Terrace, Adelaide, SA, 5000, Australia,

出版信息

Pharmacoeconomics. 2015 May;33(5):435-43. doi: 10.1007/s40273-015-0256-0.

DOI:10.1007/s40273-015-0256-0
PMID:25601288
Abstract

Given the inherent uncertainty in estimates produced by decision analytic models, the assessment of uncertainty in model-based evaluations is an essential part of the decision-making process. Although the impact of uncertainty around the choice of model structure and making incorrect structural assumptions on model predictions is noted, relatively little attention has been paid to characterising this type of uncertainty in guidelines developed by national funding bodies such as the Australian Pharmaceutical Benefits Advisory Committee (PBAC). The absence of a detailed description and evaluation of structural uncertainty can add further uncertainty to the decision-making process, with potential impact on the quality of funding decisions. This paper provides a summary of key elements of structural uncertainty describing why it matters and how it could be characterised. Five alternative approaches to characterising structural uncertainty are discussed, including scenario analysis, model selection, model averaging, parameterization and discrepancy. We argue that the potential effect of structural uncertainty on model predictions should be considered in submissions to national funding bodies; however, the characterisation of structural uncertainty is not well defined within the guidelines of these bodies. There has been little consideration of the forms of structural sensitivity analysis that might best inform applied decision-making processes, and empirical research in this area is required.

摘要

鉴于决策分析模型产生的估计值存在内在的不确定性,基于模型的评估中的不确定性评估是决策过程的重要组成部分。尽管人们注意到模型结构选择的不确定性以及做出错误的结构假设对模型预测的影响,但澳大利亚药品福利咨询委员会(PBAC)等国家资助机构制定的指南中,对这类不确定性的特征描述相对较少。缺乏对结构不确定性的详细描述和评估可能会给决策过程增加更多不确定性,对资助决策的质量产生潜在影响。本文总结了结构不确定性的关键要素,阐述了其重要性以及如何进行特征描述。讨论了五种描述结构不确定性的替代方法,包括情景分析、模型选择、模型平均、参数化和差异分析。我们认为,在向国家资助机构提交的材料中应考虑结构不确定性对模型预测的潜在影响;然而,这些机构的指南中对结构不确定性的特征描述并不明确。对于哪种结构敏感性分析形式最能为实际决策过程提供信息,几乎没有进行过考虑,因此需要在这一领域开展实证研究。

相似文献

1
Exploring structural uncertainty in model-based economic evaluations.探索基于模型的经济评估中的结构不确定性。
Pharmacoeconomics. 2015 May;33(5):435-43. doi: 10.1007/s40273-015-0256-0.
2
Model Structuring for Economic Evaluations of New Health Technologies.新型卫生技术经济评估的模型构建。
Pharmacoeconomics. 2018 Nov;36(11):1309-1319. doi: 10.1007/s40273-018-0693-7.
3
Budget impact analysis.预算影响分析。
J Med Assoc Thai. 2014 May;97 Suppl 5:S65-71.
4
"Stick or Twist?" Negotiating Price and Data in an Era of Conditional Approval.“坚持还是妥协?”在有条件批准的时代协商价格和数据。
Value Health. 2020 Feb;23(2):191-199. doi: 10.1016/j.jval.2019.09.001. Epub 2019 Dec 3.
5
A determination of topics for health technology assessment in Thailand: making decision makers involved.泰国卫生技术评估主题的确定:让决策者参与其中。
J Med Assoc Thai. 2008 Jun;91 Suppl 2:S100-9.
6
Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.经济评估中的敏感性分析:对英国国家卫生与临床优化研究所当前实践的审核及其在决策中的应用与价值综述
Health Technol Assess. 2009 Jun;13(29):iii, ix-xi, 1-61. doi: 10.3310/hta13290.
7
An introduction to the methods of cost-effectiveness analysis.成本效益分析方法介绍。
Drug Ther Bull. 2012 Jul;50(7):81-4. doi: 10.1136/dtb.2012.06.0118.
8
Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force.用于医疗保健决策的多标准决策分析——新兴良好实践:ISPOR多标准决策分析新兴良好实践工作组报告2
Value Health. 2016 Mar-Apr;19(2):125-37. doi: 10.1016/j.jval.2015.12.016. Epub 2016 Mar 7.
9
Decision analysis for resource allocation in health care.医疗保健资源分配的决策分析。
J Health Serv Res Policy. 2008 Oct;13 Suppl 3:23-30. doi: 10.1258/jhsrp.2008.008017.
10
An economic theory of the fourth hurdle.第四道门槛的经济理论。
Health Econ. 2013 May;22(5):600-10. doi: 10.1002/hec.2830. Epub 2012 Apr 30.

引用本文的文献

1
A systematic review of the current application status of decision-analytical models in the pharmacoeconomic evaluation of targeted therapies for pulmonary arterial hypertension.关于决策分析模型在肺动脉高压靶向治疗药物经济学评价中当前应用状况的系统评价
Cost Eff Resour Alloc. 2025 Apr 11;23(1):13. doi: 10.1186/s12962-025-00621-z.
2
Unravelling the Association Between Uncertainties in Model-based Economic Analysis and Funding Recommendations of Medicines in Australia.解析基于模型的经济分析中的不确定性与澳大利亚药品资助建议之间的关联。
Pharmacoeconomics. 2025 Mar;43(3):283-296. doi: 10.1007/s40273-024-01446-z. Epub 2024 Nov 15.
3

本文引用的文献

1
Decision-analytic models: current methodological challenges.决策分析模型:当前的方法学挑战。
Pharmacoeconomics. 2014 Oct;32(10):943-50. doi: 10.1007/s40273-014-0183-5.
2
The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance.结构性不确定性对辅助内分泌乳腺癌治疗成本效益模型的影响:需要针对特定疾病的模型标准化和改进指导。
Pharmacoeconomics. 2014 Jan;32(1):47-61. doi: 10.1007/s40273-013-0106-x.
3
The cloudy crystal ball of cost-effectiveness studies.
Bring Out Your Dead: A Review of the Cost Minimisation Approach in Health Technology Assessment Submissions to the Australian Pharmaceutical Benefits Advisory Committee.
《唤醒死者:对澳大利亚药品福利咨询委员会健康技术评估提交物中成本最小化方法的评价》
Pharmacoeconomics. 2024 Nov;42(11):1287-1300. doi: 10.1007/s40273-024-01420-9. Epub 2024 Aug 24.
4
Impact of Structural Differences on the Modeled Cost-Effectiveness of Noninvasive Prenatal Testing.结构差异对无创性产前检测模型成本效益的影响。
Med Decis Making. 2024 Oct;44(7):811-827. doi: 10.1177/0272989X241263368. Epub 2024 Aug 2.
5
Response to uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group - author's reply.药物监管与卫生技术评估决策中不确定性管理的应对措施:HTAi-DIA工作组指南——作者回复
Int J Technol Assess Health Care. 2023 Dec 18;40(1):e1. doi: 10.1017/S0266462323002817.
6
Response to "UNCERTAINTY MANAGEMENT IN REGULATORY AND HEALTH TECHNOLOGY ASSESSMENT DECISION-MAKING ON DRUGS: GUIDANCE OF THE HTAi-DIA WORKING GROUP".对《药品监管与卫生技术评估决策中的不确定性管理:HTAi-DIA 工作组指南》的回应
Int J Technol Assess Health Care. 2023 Oct 12;39(1):e70. doi: 10.1017/S026646232300260X.
7
How Sensitive is Sensitivity Analysis?: Evaluation of Pharmacoeconomic Submissions in Korea.敏感性分析的敏感度如何?:韩国药物经济学申报文件评估
Front Pharmacol. 2022 May 16;13:884769. doi: 10.3389/fphar.2022.884769. eCollection 2022.
8
Calibrating Natural History of Cancer Models in the Presence of Data Incompatibility: Problems and Solutions.在存在数据不兼容的情况下校准癌症模型的自然史:问题与解决方案。
Pharmacoeconomics. 2022 Apr;40(4):359-366. doi: 10.1007/s40273-021-01125-3. Epub 2022 Jan 7.
9
Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data.使用患者水平模拟模型推断临床试验数据时准确反映不确定性。
Med Decis Making. 2020 May;40(4):460-473. doi: 10.1177/0272989X20916442. Epub 2020 May 20.
10
Model Structuring for Economic Evaluations of New Health Technologies.新型卫生技术经济评估的模型构建。
Pharmacoeconomics. 2018 Nov;36(11):1309-1319. doi: 10.1007/s40273-018-0693-7.
成本效益研究的朦胧水晶球。
Value Health. 2013 Sep-Oct;16(6):1100-2. doi: 10.1016/j.jval.2013.06.012.
4
Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6.模型参数估计和不确定性:ISPOR-SMDM 建模良好实践工作组的报告——6.
Value Health. 2012 Sep-Oct;15(6):835-42. doi: 10.1016/j.jval.2012.04.014.
5
Improving the accuracy and comparability of model-based economic evaluations of health technologies for reimbursement decisions: a methodological framework for the development of reference models.改进基于模型的卫生技术报销决策经济评价的准确性和可比性:参考模型制定的方法学框架。
Med Decis Making. 2013 Apr;33(3):325-32. doi: 10.1177/0272989X12458160. Epub 2012 Sep 7.
6
A proposed model for economic evaluations of major depressive disorder.一种用于评估重度抑郁症的经济评价模型。
Eur J Health Econ. 2012 Aug;13(4):501-10. doi: 10.1007/s10198-011-0321-3. Epub 2011 Jun 2.
7
A framework for addressing structural uncertainty in decision models.用于解决决策模型中结构不确定性的框架。
Med Decis Making. 2011 Jul-Aug;31(4):662-74. doi: 10.1177/0272989X11406986. Epub 2011 May 20.
8
Model averaging in the presence of structural uncertainty about treatment effects: influence on treatment decision and expected value of information.存在治疗效果结构不确定性时的模型平均:对治疗决策和信息期望价值的影响。
Value Health. 2011 Mar-Apr;14(2):205-18. doi: 10.1016/j.jval.2010.08.001.
9
Calibrating models in economic evaluation: a comparison of alternative measures of goodness of fit, parameter search strategies and convergence criteria.校准经济评估模型:拟合优度、参数搜索策略和收敛标准的替代度量方法比较。
Pharmacoeconomics. 2011 Jan;29(1):51-62. doi: 10.2165/11584610-000000000-00000.
10
Exploring model uncertainty in economic evaluation of health interventions: the example of rotavirus vaccination in Vietnam.探讨健康干预经济评估中的模型不确定性:以越南轮状病毒疫苗接种为例。
Med Decis Making. 2010 Sep-Oct;30(5):E1-E28. doi: 10.1177/0272989X10375579. Epub 2010 Aug 20.